Apollo Hospitals Enterprise Ltd

Profit before tax (PBT) increased 27.19% YoY to Rs 682 crore in the quarter ended 31 December 2025. EBITDA grew by 26.64% to Rs 965 crore in Q3 FY26, up from Rs 762 crore in Q3 FY25. This includes Apollo 24/7 costs of Rs 124 crore during the quarter (including Rs 38 crore in non-cash ESOP charges), compared to Rs 141 crore in Q3 FY25. On a segmental front, revenue from Healthcare Services rose 14% YoY to Rs 3,183 crore. Revenue from Apollo Health and Lifestyle (AHLL) stood at Rs 467 crore, up 20% YoY, while revenue from Apollo HealthCo reached Rs 2,827 crore, also up 20% YoY. As on 31 December 2025, Apollo Hospitals had 8,072 operating beds across the network (excluding AHLL & managed beds). The overall occupancy for hospitals was at 67% in Q3FY26 vs 68% in the same period in the previous year. Dr. Prathap C Reddy, Chairman, Apollo Hospitals Enterprise Ltd. said, 'Q3FY26 reflects the fundamental strength and clinical depth of Apollo's integrated care model. Across our network, teams are consistently delivering strong outcomes through disciplined execution in patient safety, quality, and experience. This quarter, sustained investments in advanced clinical capability translated into meaningful progress across key specialties from Apollo OMR completing 150 robotic joint replacement surgeries in its first 150 days, to the expansion of our stroke care network in Chennai with nine advanced stroke labs, strengthening rapidaccess care and outcomes. We further reinforced our differentiated leadership in neurosciences with the launch of a dedicated Centre of Excellence for Parkinson's disease and Deep Brain Stimulation care in Chennai, strengthened comprehensive oncology care through the 'Save My Stomach' early detection programme at Apollo Cancer Centres, and expanded high-acuity capability with a dedicated heart and lung transplant unit in Karnataka. In parallel, partnerships such as the MoU with Coal India reflect Apollo's vision to expand access to standardized, high-quality healthcare by building integrated preventive and tertiary care pathways for large workforce populations. Apollo's transplant programme reflects the depth, scale, and discipline of our clinical systems. As one of the world's busiest solid organ transplant programmes, our teams now perform an average of five solid organ transplants each day. Cumulatively, we have completed more than 21,000 kidney transplants and over 5,000 liver transplants'becoming the first hospital group in India and the region to reach this landmark'along with 159 heart transplants and 232 lung transplants. These outcomes are the result of standardized clinical pathways, multidisciplinary expertise, and a sustained commitment to patient safety, ethics, and long-term outcomes. The Union Budget provides an important tailwind to India's aspiration to become a global destination for healthcare. The proposal to support states in establishing five regional medical hubs through public' private partnership is a strategic step toward building a high-quality, well-coordinated Medical Value Travel ecosystem. At Apollo, we view Medical Value Travel as a long-term national mission that reflects India's depth of clinical expertise, outcomes excellence, and cost advantage. We will continue to work closely with policymakers and state partners to strengthen international patient pathways, expand high-acuity capacity, and ensure seamless coordination across pre-travel evaluation, clinical care, and post-discharge followup.' The board has declared an interim dividend of Rs 10 per share for the financial year 2026. The record date for the same has been fixed as February 16 and it will be paid on or before February 27. Apollo Hospitals was established in 1983 by Dr. Prathap C Reddy, renowned architect of modern healthcare in India. As the nation's first corporate hospital, Apollo Hospitals is acclaimed for pioneering the private healthcare revolution in the country. Apollo Hospitals has emerged as Asia's foremost integrated healthcare services provider and has a robust presence across the healthcare ecosystem, including Hospitals, Pharmacies, Primary Care & Diagnostic Clinics and several Retail Health models. Powered by Capital Market - Live

Net profit of Apollo Hospitals Enterprise rose 34.92% to Rs 502.30 crore in the quarter ended December 2025 as against Rs 372.30 crore during the previous quarter ended December 2024. Sales rose 17.20% to Rs 6477.40 crore in the quarter ended December 2025 as against Rs 5526.90 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales6477.405526.90 17 OPM %14.9013.78 - PBDT920.40720.80 28 PBT701.20536.20 31 NP502.30372.30 35 Powered by Capital Market - Live

Apollo Hospitals Enterprise announced that the Board of Directors of the Company at its meeting held on 10 February 2026, has recommended a Interim Dividend of Rs.10 per share (i.e.200%), subject to the approval of the shareholders.Powered by Capital Market - Live

Apollo Hospitals Enterprise will hold a meeting of the Board of Directors of the Company on 10 February 2026.Powered by Capital Market - Live

Net profit of Apollo Hospitals Enterprise rose 25.98% to Rs 477.20 crore in the quarter ended September 2025 as against Rs 378.80 crore during the previous quarter ended September 2024. Sales rose 12.78% to Rs 6303.50 crore in the quarter ended September 2025 as against Rs 5589.30 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales6303.505589.30 13 OPM %14.9314.59 - PBDT892.50741.90 20 PBT674.70557.40 21 NP477.20378.80 26 Powered by Capital Market - Live

Apollo Hospitals Enterprise will hold a meeting of the Board of Directors of the Company on 6 November 2025.Powered by Capital Market - Live

The aforementioned stake sale was executed through a block deal on the stock exchanges, at a price of Rs 7850 per share, a discount of nearly 1% to the closing price yesterday. Accordingly, the total value of the said transaction is Rs 1,489.33 crore The sale proceeds will be utilised to pare down outstanding debt of the Promoter Group. Subsequent to the sale, the Promoter Group holding in Apollo Hospitals will reduce to nearly 28% (from the current 29.3%) and pledged holdings of the Promoter Group (as a percentage of their total holding) will reduce from 13.1% to approximately 2%. The transaction fulfils a commitment made to investors to reduce the pledge,' the company said in a statement. The company further added that the Promoter Group does not have any plan of any further stake reduction in the foreseeable future. Apollo Hospitals Enterprise has established a strong presence across the healthcare ecosystem, encompassing hospitals, pharmacies, primary care and diagnostic clinics, as well as various retail health models. The Group also offers telemedicine services in multiple countries, health insurance solutions, global project consultancy, and operates medical colleges, a nursing and hospital management college, and Medvarsity for e-learning. The company reported 41.80% surge in consolidated net profit to Rs 432.80 crore on 14.87% increase in revenue from operations to Rs 5,842.10 crore in Q1 FY26 over Q1 FY25. The scrip shed 0.20% to currently trade at Rs 7909.50 on the BSE. On the NSE, 2.29 lakh shares of the company were traded at the counter so far as against the three-month average trading volume of 4.78 lakh shares. On the BSE, 4437 shares of the company had changed hands at the counter as compared with the two-week average trading volume of 0.26 lakh shares. Powered by Capital Market - Live

Profit before tax (PBT) increased 35.51% YoY to Rs 582.70 crore in the quarter ended 30 June 2025. EBITDA grew by 26.22% to Rs 852 crore in Q1 FY26, up from Rs 675 crore in Q1 FY25. This includes Apollo 24/7 costs of Rs 121 crore during the quarter (including Rs 24 crore in non-cash ESOP charges), compared to Rs 150 crore in Q1 FY25. On segmenetal front, revenue from healthcare services rose 11% YoY to Rs 2,935 crore. Revenue from Apollo Health and Lifestyle (AHLL) stood at Rs 435 crore, up 19% YoY, while revenue from Apollo HealthCo reached Rs 2,472 crore, also up 19% YoY. As of 30 June 2025, Apollo Hospitals had 8,030 operating beds across its network (excluding AHLL and managed beds). Overall hospital occupancy was at 65%, compared to 68% in the same period last year. Dr. Prathap C Reddy, chairman, Apollo Hospitals Enterprise, said: I am proud to see the resilient comeback in the first quarter of FY26, building on the strong foundation of Q4 FY25. I am glad to inform you that Q1 FY26 has delivered another robust set of results, with revenue growth in the double digits at 15% YoY and continued improvement in margins. Our performance demonstrates the power and resilience of our integrated model of healthcare delivery with all three engines - our core divisions, Healthcare Services, Retail Healthcare & Diagnostics, and Digital & Pharma Distribution, contributing to our performance. Patient numbers across our network increased year-on-year, reflecting both the deeper penetration of our Centers of Excellence and the growing confidence of communities in our integrated care model. The quarter saw us announce our ambitious growth strategy to add over 4,300 beds in the next five years with an investment of over 7,600 crore. The first phase of 2,000 beds is already in progress. We have added an existing 200-bed hospital in Bengaluru and will also be establishing a 500-bed greenfield hospital in the suburbs of the city to bring the total bed strength in Bengaluru to 1,500 beds. In Hyderabad, we are adding 160 beds at our existing Jubilee Hills and Secunderabad facilities, and with the upcoming facility in Gachibowli, our bed strength in the city will increase to 1,400 beds. On the digital front, Apollo 24/7 achieved a quarterly GMVof over Rs 682 crore, sustaining the platform's momentum and signaling the continuing strong demand for teleconsultetions, lab and pharmacy deliveries. This performance builds on the platform's FY25 GMV of Rs. 3,007 crore, demonstrating our success in creating a seamless care continuum from home to hospital. The demerger of our digital health and pharmacy business, approved in the last quarter, is now in the implementation phase. This strategic move will enable focused capital allocation and sharper growth plans with dedicated management teams for both hospital operations and omnichannel healthcare ecosystem, a structure designed to maximize synergies while preserving the Apollo ethos of quality and trust. Preventive healthcare remains at the heart of our mission. Through the Al-based Apollo ProHealth platform, we have crossed 25Million health assessments this quarter alone, guiding individuals on personalized wellness journeys and strengthening early -detection pathways. Patient access continues to guide our investments. We expanded our 'Care-Within-Reach' financing programs to additional tier2 and tier3 markets, ensuring that advanced treatments remain accessible to a broad segment of the population. Our efforts on sustainability saw us launch 'Green Health' initiatives in Mumbai and Hyderabad, achieving a 20% reduction in energy consumption per patient day and using ecofriendly materials across new construction projects. Looking ahead, we anticipate continued double digit revenue growth for FY26, underpinned by new hospital openings in Patna and Jaipur slated for QJ, further digital innovation, and deepening partnerships with state governments to bolster community-based health initiatives. I remain confident that Apollo will set new benchmarks in clinical excellence, patient experience, and sustainable growth-true to our founding mission of enabling healthier, happier lives for all. Meanwhile, the board of directors of the company has approved an investment of an amount not exceeding a sum of Rs 85 million for acquiring 85,00,000 equity shares of Rs 10 each of Apollo Gleneagles PET-CT Private (AGPCL) from its existing shareholder, Parkway Healthcare (Mauritius) PTE, representing 50% of the total paid-up equity share of AGPCL. Apollo Hospitals Enterprise has established a strong presence across the healthcare ecosystem, encompassing hospitals, pharmacies, primary care and diagnostic clinics, as well as various retail health models. The Group also offers telemedicine services in multiple countries, health insurance solutions, global project consultancy, and operates medical colleges, a nursing and hospital management college, and Medvarsity for e-learning. Additionally, it is supported by a dedicated research foundation. Powered by Capital Market - Live

Securities in F&O Ban: PG Electroplast, PNB Housing Finance, RBL Bank and Titagarh Rail Systems are banned from F&O trading on 13 August 2025. Upcoming Results: Bharat Petroleum Corporation, Pfizer, Deepak Nitrite, Brigade Enterprises, Aditya Birla Fashion and Retail, Samvardhana Motherson Internaional, AIA Engineering, Anupam Rasayan India, Astra Microwave Products, Avanti Feeds, Bhansali Engineering Polymers, Campus Activewear, CSB Bank, Dredging Corporation of India, Endurance Technologies Engineers India, Fiem Industries, Brainbees Solutions, Jubilant Foodworks, United Spirits will announce their result later today. Stocks to Watch: Apollo Hospitals Enterprise's consolidated net profit jumped 53.5% to Rs 389.60 crore on 13.1% increase in net sales to Rs 5592.20 crore in Q1 FY26 over Q1 FY25. ONGC's consolidated net profit fell 1.7% to Rs 9,804.07 crore on 3.5% decline in net sales to Rs 1,63,108.13 crore in Q1 FY26 over Q1 FY25. Jindal Steel & Power reported a 11.5% increase in consolidated net profit to Rs 1,493.97 crore in Q1 FY26 compared with Rs 1,340.15 crore in Q1 FY25. Net sales fell 9.7% YoY to Rs 12,294.48 crore during the quarter. Suzlon Energy 's consolidated net profit rose 7.3% to Rs 324.32 crore on 54.6% jump in net sales to Rs 3117.33 crore in Q1 June 2025 over Q1 June 2024. FSN E-commerce(Nykaa)'s consolidated net profit surged 141.9% to Rs 23.32 crore during the quarter, compared with Rs 9.64 crore in Q1 FY25. Net sales increased 23.4% YoY to Rs 2,154.94 crore in Q1 FY26. National Securities Depository (NSDL) reported a 7.6% jump in consolidated net profit to Rs 89.63 crore despite of 14.18% decline in net sales to Rs 312.03 crore in Q1 FY26 over Q4 FY25.Powered by Capital Market - Live

Net profit of Apollo Hospitals Enterprise rose 41.81% to Rs 432.80 crore in the quarter ended June 2025 as against Rs 305.20 crore during the previous quarter ended June 2024. Sales rose 14.88% to Rs 5842.10 crore in the quarter ended June 2025 as against Rs 5085.60 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales5842.105085.60 15 OPM %14.5813.27 - PBDT797.40607.40 31 PBT582.70430.00 36 NP432.80305.20 42 Powered by Capital Market - Live